HY-0721

HY-0721 is an investigational small molecule drug candidate being developed by Suzhou Pharmavan Cancer Research Center for the treatment of acute ischemic stroke. Currently in Phase 1 clinical development, the agent is designed to provide therapeutic benefit following a stroke event, likely through neuroprotective mechanisms, although its specific molecular target has not been publicly disclosed. The development of HY-0721 represents an expansion of Suzhou Pharmavan's research focus into the central nervous system therapeutic area, leveraging its pipeline to address critical unmet needs in stroke recovery and management.